Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,831,498 papers from all fields of science
Search
Sign In
Create Free Account
5,8-dideazaisofolic acid
Known as:
IAHQ
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
5,8-dideazaisopteroylglutamate
Broader (1)
Quinazolines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Synthesis and biological evaluation of analogues of 5,8-dideazaisofolic acid (IAHQ) modified at positions 2, 4 and 9.
J. Hynes
,
R. L. Hagan
,
B. Shane
,
J. Freisheim
Advances in Experimental Medicine and Biology
1993
Corpus ID: 41070099
The compound 5,8-dideazaisofolic acid (IAHQ), 1a, was found to posses modest antitumor activity against a variety of human and…
Expand
1987
1987
Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells.
J. McGuire
,
A. Sobrero
,
J. Hynes
,
J. Bertino
Cancer Research
1987
Corpus ID: 15163439
The clonal cytotoxic effects and mechanism of action of a new series of 2-amino-4-hydroxyquinazoline folate analogues (5,8…
Expand
1986
1986
Dissociation of thymidylate biosynthesis from DNA biosynthesis by 5-fluoro-2'-deoxyuridine and 5,8-dideazaisofolic acid.
D. Fernandes
,
S. Cranford
Cancer Research
1986
Corpus ID: 21206735
The effects of 5-fluoro-2'-deoxyuridine (FdUrd) and 5,8-dideazaisofolic acid on the coordination of thymidylate synthase activity…
Expand
1986
1986
Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
A. Sobrero
,
J. Bertino
The International Journal Of Cell Cloning
1986
Corpus ID: 1934862
None of 13 fresh human tumor samples of various histology cloned in a two-layer agar culture system with 20% undialyzed fetal…
Expand
Highly Cited
1985
Highly Cited
1985
Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
E. Mini
,
B. Moroson
,
Christine T. Franco
,
J. R. Bertino
Cancer Research
1985
Corpus ID: 25795186
A human T-lymphoblast cell line, CCRF-CEM/R1, resistant to methotrexate by virtue of increased dihydrofolate reductase activity…
Expand
1984
1984
Improved synthesis and antitumor evaluation of 5,8-dideazaisofolic acid and closely related analogues.
J. Hynes
,
Yuh Cheng Yang
,
J. Mcgill
,
S. Harmon
,
W. Washtien
Journal of Medicinal Chemistry
1984
Corpus ID: 10020182
A new synthetic route to 5,8-dideazaisofolic acid (IAHQ) is described which precludes the possibility of contamination due to its…
Expand
1983
1983
Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase.
D. Fernandes
,
J. Bertino
,
J. Hynes
Cancer Research
1983
Corpus ID: 11745704
Abstract The effects of 5,8-dideazaisopteroylglutamate ( N -[ p -{[(2-amino-4-hydroxy-6-quinazolinyl)amino]methyl}benzoyl]-l…
Expand
1983
1983
Improved synthetic routes to 5,8-dideazapteroylglutamates amenable to the formation of poly-gamma-L-glutamyl derivatives.
J. Hynes
,
Y. C. Yang
,
G. McCue
,
M. B. Benjamin
Advances in Experimental Medicine and Biology
1983
Corpus ID: 25711490
A variety of quinazoline analogues of folic acid (5,8-dideazafolates) are of interest as potential antineoplastic agents…
Expand
1982
1982
Effects of 5,8-dideazaisofolic acid (IAHQ) on human tumor cells in culture and on normal and tumor-bearing hamsters.
K. Tsang
,
J. Hynes
,
H. Fudenberg
Chemotherapy
1982
Corpus ID: 3269128
The quinazoline analog of folic acid, 5,8-dideazaisofolic acid (IAHQ), was tested for its effects on the growth of human tumor…
Expand
1981
1981
5,8-Dideazaisofolic acid
J. Castañer
,
Daniel J. Fernandes
,
John B. Hynes
,
R. M. Cárdenas
,
Joseph R. Bertino
1981
Corpus ID: 76024299
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE